Phase 1 Trial of 3-2,4 Dimethoxbenzylidene Anabaseine [GTS-21] in Schizophrenia

Trial Profile

Phase 1 Trial of 3-2,4 Dimethoxbenzylidene Anabaseine [GTS-21] in Schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2015

At a glance

  • Drugs GTS 21 (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 14 Nov 2013 Planned end date changed from 1 Sep 2009 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 02 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top